🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 37 of 857 · Phase 3 first, then by program name

  1. CHIKV VLP vaccine

    Bavarian Nordic A/S

    Chikungunya Virus

    phase 3 mab active

    2 trials

  2. CHLORAMBUCIL, FLUDARABINE PHOSPHATE, Lisaftoclax, ACALABRUTINIB, Lisaftoclax, Lisaftoclax, RITUXIMAB, CYCLOPHOSPHAMIDE MONOHYDRATE, RITUXIMAB

    Lacuna Pharma Pty Ltd

    Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  3. CHLORURE DE POTASSIUM B. BRAUN 10 % (0,10 g/ml), solution à diluer pour perfusion, GLUCOSE 2,5 % B. BRAUN, solution pour perfusion, MINIRIN 4 microgrammes/ml, solution injectable, SODIUM LACTATE, CHLORURE DE SODIUM 0,9 % AGUETTANT, solution pour perfusion, CHLORURE DE SODIUM HYPERTONIQUE 10 % LAVOISIER, solution à diluer injectable, GLUCOSE 5 % VIAFLO, solution pour perfusion, GADOTERIC ACID

    Pari Pharma GmbH

    Severe hyponatremia and a high risk of rapid SNa overcorrection

    phase 3 small molecule active

    1 trial

  4. CHLORURE DE SODIUM 0,9 % B. BRAUN, solution injectable en ampoule, TOCILIZUMAB

    Pari Pharma GmbH

    Sickle cell disease

    phase 3 small molecule active

    1 trial

  5. CHLORURE DE SODIUM 0,9% RENAUDIN, solution injectable, VENLAFAXINE, KETAMINE , 11C-UCB-J

    Pari Pharma GmbH

    Major depressive disorder with current severe major depressive episode

    phase 3 small molecule active

    1 trial

  6. CHLORURE DE SODIUM FRESENIUS 0,9 %, solution injectable, Tislelizumab

    The George Institute

    patients with a positive status for molecular residual disease (MRD) [MRD (+)] 2 to 5 months after the end of standard end of standard curative treatment

    phase 3 small molecule active

    1 trial

  7. CHS-0214

    Coherus Oncology

    Rheumatoid Arthritis

    phase 3 small molecule completed

    1 trial

  8. CHS-1420

    Coherus Oncology

    Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  9. CI-581a

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorder

    phase 3 small molecule on hold

    1 trial

  10. CINRYZE 500

    Takeda

    Hereditary Angioedema (HAE)

    phase 3 mab completed

    1 trial

  11. CINRYZE 500 U

    Takeda

    Hereditary Angioedema (HAE)

    phase 3 small molecule completed

    1 trial

  12. CIPROFLOXACIN, Upadacitinib, Upadacitinib, METHOTREXATE, SULFASALAZINE, Upadacitinib, Upadacitinib, DEXAMETHASONE, Upadacitinib

    AbbVie Deutschland GmbH & Co. KG

    Crohn's Disease (CD)

    phase 3 small molecule active

    1 trial

  13. CISPLATIN

    Ningbo Cancer Hospital

    Ovarian epithelial cancer : intraperitoneal resectable relapse

    phase 3 small molecule active

    1 trial

  14. CISPLATIN , PACLITAXEL , GEMCITABINE , CARBOPLATIN , placebo for mRNA-4157, PEMETREXED , mRNA-4157, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  15. CISPLATIN, Armisarte 25 mg/ml concentrate for solution for infusion, CARBOPLATIN, PEMETREXED, TAGRISSO 80 mg film-coated tablets, PLACEBO, TAGRISSO 40 mg film-coated tablets

    AstraZeneca AB

    Patients with histologically or cytologically documented non-squamous NSCLC with completely resectable (Stage II - IIIB N2) disease

    phase 3 small molecule active

    1 trial

  16. CISPLATIN, BL-B01D1, GEMCITABINE, PEGFILGRASTIM, CARBOPLATIN

    Bristol-Myers Squibb Australia Pty Ltd

    Metastatic urothelial cancer

    phase 3 small molecule active

    1 trial

  17. CISPLATIN, CARBOPLATIN

    Cardiff Oncology

    Human papillomavirus (HPV)-positive oropharyngeal cancer

    phase 3 small molecule active

    1 trial

  18. CISPLATIN, CARBOPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL, GEMCITABINE, IMJUDO 20 mg/ml concentrate for solution for infusion., INFLIXIMAB, GEMCITABINE

    AstraZeneca AB

    Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer

    phase 3 small molecule active

    1 trial

  19. CISPLATIN, CISPLATIN, Telisotuzumab adizutecan, OSIMERTINIB, PEMETREXED, CARBOPLATIN, CISPLATIN, AMIVANTAMAB, AMIVANTAMAB, CARBOPLATIN, CARBOPLATIN, PEMETREXED, OSIMERTINIB, PEMETREXED

    AbbVie Deutschland GmbH & Co. KG

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  20. CISPLATIN, FLUOROURACIL, MITOMYCIN, CAPECITABINE, CAPECITABINE, DOCETAXEL

    CERO THERAPEUTICS HOLDINGS, INC.

    locally advanced anal squamous cell carcinoma

    phase 3 small molecule active

    1 trial

  21. CISPLATIN, GEMCITABINE, INFLIXIMAB, Rilvegostomig, IMFINZI 50 mg/mL concentrate for solution for infusion., DS-8201a, MYCOPHENOLATE MOFETIL

    AstraZeneca AB

    Advanced HER2-expressing Biliary Tract Cancer

    phase 3 small molecule active

    1 trial

  22. CISPLATIN, INFLIXIMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., GEMCITABINE, MYCOPHENOLATE MOFETIL

    AstraZeneca AB

    First-line patients with advanced biliary tract cancers (BTC)

    phase 3 small molecule active

    1 trial

  23. CISPLATIN, TAGRISSO 40 mg film-coated tablets, Datopotamab deruxtecan, TAGRISSO 80 mg film-coated tablets, CARBOPLATIN, PEMETREXED

    AstraZeneca AB

    Non squamous non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  24. CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, OPDIVO 10 mg/mL concentrate for solution for infusion., Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, GEMSOL, 40 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI

    Bristol-Myers Squibb Australia Pty Ltd

    Bladder Cancer Muscle-Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources